Our Approach

New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More


October 12, 2021
VUV Analytics, Inc. Introduces the LUMA™ Multi-Channel Vacuum Ultraviolet Absorbance Detector

VUV Analytics, Inc. has introduced the VUV LUMA Multi-Channel Vacuum Ultraviolet Absorbance Detector, providing best-in-class detector sensitivity, universal detection, and selectivity that seamlessly integrates into existing laboratory workflows. “LUMA represents the next logical step in our long-term product strategy,” said Clark Jernigan, CEO of VUV Analytics. “Since the introduction of our

Read More
October 6, 2021
BrightVolt raises $16 million in Series B funding led by New Science Ventures and Caterpillar Venture Capital Inc.

BrightVolt, Inc., a global leader in the design, development, and manufacturing of safe, high energy and low cost solid-state Lithium-Ion batteries has successfully closed the first tranche of a $16M Series B financing round with significant investments by New Science Ventures (NSV) and Caterpillar Venture Capital Inc. (Caterpillar). Fresh funds

Read More
September 20, 2021
Ventyx Biosciences announces key appointments and closing of $51m Series B financing

Ventyx Biosciences, Inc. (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, has announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief

Read More
July 20, 2021
VORAGO Technologies announces low-cost and immediately available rad-tolerant hi-rel MCU for New Space, LEO market

VORAGO Technologies (https://voragotech.com) has announced a product portfolio expansion to include a new radiation-tolerant Arm® Cortex-M0 MCU, VA10805, as a cost-competitive and high reliability solution for LEO, New Space, SmallSat and CubeSat markets. "As commercialization of space continues to grow, so does the need for reliable, affordable, and immediately available

Read More
June 30, 2021
Isorg raises €16 million in Series C financing

Isorg, a pioneer in Organic Photodetectors (OPDs) and large-area image sensors, has announced a capital increase of €16M in series C financing. Two major industrial investors, Sumitomo Chemical Co. Ltd and Mitsubishi Corporation, participated in the round. Greece-based Integrated Systems Development SA and five new French investors represented by fund

Read More
June 30, 2021
Bioasis Technologies Inc and Oxyrane UK Ltd enter into a Research Collaboration

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis”) and Oxyrane UK Ltd (“Oxyrane”) are pleased to announce the initiation of a research collaboration. Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS

Read More
June 23, 2021
Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid. It is estimated that up to 30% of patients

Read More
June 17, 2021
Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world

Zeotap, the leading Customer Data Platform, has launched a new integration with Google Customer Match, enabling marketers to leverage their first-party data to engage audiences at scale across Google Search, Shopping, Gmail, YouTube and Display. In doing so, the new integration provides an important solution to addressability when third-party cookies

Read More
June 14, 2021
CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production

Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership

Read More
June 11, 2021
Phase Four raises $26m led by New Science Ventures

Phase Four, the creator of the radio-frequency thruster for satellite propulsion, announced today that it has closed a Series B investment round of $26 million. The round was led by New Science Ventures LLC ("NSV"), a leading venture capital firm focused on building companies that leverage breakthrough science to create

Read More
May 12, 2021
Zeotap launches Predictive Audiences to empower marketers with machine learning

Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive

Read More
May 11, 2021
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal

Read More
April 14, 2021
Zeotap builds momentum as marketing industry shifts away from cookies

Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the

Read More
April 8, 2021
Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range of applications including AI/ML, 5G infrastructure, networking,

Read More
March 25, 2021
ABL Space raises $170m growth equity round led by T. Rowe Price funds

ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors and new investments by Fidelity Management & Research

Read More
March 16, 2021
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor.  In non-clinical studies, VTX-958 has shown potential to treat autoimmune diseases by

Read More
March 9, 2021
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million

New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs. Ventyx Biosciences combines assets from three formerly

Read More
March 8, 2021
iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI® was presented at the European Congress of Radiology (ECR) 2021 Online meeting, taking place March 3-10, 2021. During the congress, the Company also showcased the full suite

Read More
March 8, 2021
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition Profile (FAP) 10 module has received FBI certification, the first in this category of organic photodiode (OPD) based optical sensors. The FAP 10 biometrics module is now approved for use in security applications, in

Read More
March 8, 2021
iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us


500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845


16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100